On February 6, 2018 Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, reported it will host a Program Update on Tuesday, February 27th from 10:00 a.m. – 12:00 p.m. Eastern Time (ET) at the Lotte New York Palace in New York, NY (Press release, Sierra Oncology, FEB 6, 2018, View Source [SID1234523747]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the event, the senior management team from Sierra Oncology will present a strategic update on the development programs for its two DDR drug candidates: SRA737, a highly selective, orally bioavailable Chk1 inhibitor; and SRA141, a highly selective, orally bioavailable Cdc7 inhibitor. The company will be joined by Dr. Udai Banerji, Chief Investigator for Sierra’s ongoing SRA737 Phase 1/2 clinical studies, and Dr. Alan D’Andrea, a member of Sierra’s DDR Advisory Committee.
Dr. Udai Banerji is the Cancer Research UK Reader in Molecular Cancer Pharmacology at The Institute of Cancer Research, London, and a Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust. He leads the Clinical Pharmacology and Trials team at The Institute of Cancer Research (ICR) and is the Deputy Director of the Drug Development Unit at the ICR and The Royal Marsden.
Dr. Alan D’Andrea is the Fuller-American Cancer Society Professor of Radiation Oncology at Harvard Medical School and the Director of the Center for DNA Damage and Repair at the Dana-Farber Cancer Institute. Dr. D’Andrea is internationally known for his research in the area of DNA damage and DNA repair, and participates in a wide range of clinical trials, largely focused on ovarian, breast, prostate, and bladder cancers.
Event registration and webcast information are available through the Sierra Oncology website at www.sierraoncology.com. An archive of the presentation will be accessible after the event through the Sierra Oncology website.
BIO CEO & Investor Conference in New York
Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company, scheduled for 11:30 a.m. ET on Monday, February 12th at the BIO CEO & Investor Conference being held in New York, NY. A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com.